Επιστημονικό & Ερευνητικό Έργο της Greek Research Alliance for the Study of Headache and Pain (the GRASP Study Group)
Τρέχοντα επιστημονικά και ερευνητικά προγράμματα
An observational, open label study on the use of a fixed sumatriptan/naproxen combination in acute migraine attacks (manuscript in preparation)
Comparing the efficacy and safety of anti-CGRP monoclonal antibodies versus topiramate for migraine prophylaxis: Six-month, real-world, intention-to-treat retrospective evidence from the GRASP study group (manuscript accepted for publication)
Δημοσιευμένα Άρθρα
Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.
Dermitzakis EV, Argyriou AA, Chondrogianni M, Foska A, Rikos D, Athanasopoulos D, Tsironis C, Soldatos P, Koutsokera M, Tsitsaras N, Litsardopoulos P, Mavraki E, Vikelis M; Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
J Headache Pain. 2026 Jan 23;27(1):48.
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group.
Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Soldatos P, Vikelis M; Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
J Clin Med. 2025 Dec 12;14(24):8793.
OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group.
Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Xiromerisiou G, Soldatos P, Litsardopoulos P, Vikelis M; Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
Toxins (Basel). 2025 Nov 3;17(11):547.
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Chondrogianni M, Foska A, Soldatos P, Mavraki E, Rikos D, Litsardopoulos P, Tsivgoulis G, Vikelis M.
Eur J Neurol. 2025 Aug;32(8):e70327.
Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis.
Vikelis M, Rikos D, Argyriou AA, Dermitzakis EV, Andreou AP, Russo A.
Expert Rev Neurother. 2025 Feb 5:1-16.
Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study.
Dermitzakis EV, Rikos D, Vikelis M, Xiromerisiou G, Zisopoulou S, Rallis D, Soldatos P, Vlachos GS, Vasiliadis GG, Argyriou AA.
Brain Sci. 2024 Nov 22;14(12):1169.
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rikos D, Rallis D, Soldatos P, Litsardopoulos P, Andreou AP, Vikelis M.
Expert Rev Neurother. 2024 Nov;24(11):1119-1126.
Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.
Vikelis M, Rikos D, Argyriou AA, Papachristou P, Rallis D, Karapanayiotides T, Galanopoulos A, Spingos K, Dimisianos N, Giakoumakis E, Zavridis P, Notas K, Vlachos GS, Soldatos P, Bilias K, Xiromerisiou G, Rudolf J, Dermitzakis EV, Rapoport AM.
Expert Rev Neurother. 2024 Aug;24(8):815-826.
Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options.
Dermitzakis EV, Argyriou AA, Bilias K, Barmpa E, Liapi S, Rikos D, Xiromerisiou G, Soldatos P, Vikelis M.
J Clin Med. 2024 May 8;13(10):2768.
Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.
Rikos D, Vikelis M, Dermitzakis EV, Soldatos P, Rallis D, Rudolf J, Andreou AP, Argyriou AA.
J Clin Med. 2024 Mar 28;13(7):1964.
Effects of OnabotulinumtoxinA on Allodynia and Interictal Burden of Patients with Chronic Migraine.
Argyriou AA, Dermitzakis EV, Rikos D, Xiromerisiou G, Soldatos P, Litsardopoulos P, Vikelis M.
Toxins (Basel). 2024 Feb 15;16(2):106.
Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine.
Dermitzakis EV, Vikelis M, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Rikos D, Argyriou AA.
J Clin Med. 2024 Jan 10;13(2):386.
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.
Vikelis M, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Rikos D, Argyriou AA.
J Clin Med. 2023 Jul 6;12(13):4526.
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry.
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Vikelis M.
J Clin Med. 2023 Apr 29;12(9):3218.
A Survey of Greek Primary Care Physicians on Their Likeability in Treating Migraines and Other Common Diseases.
Vikelis M, Argyriou AA, Antoniou A, Spingos KC, Skliros AE, Bilias K, Kouroudi A, Dermitzakis EV, Skliros EA.
Medicina (Kaunas). 2023 Apr 9;59(4):734.
Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry.
Argyriou AA, Dermitzakis EV, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, Vikelis M.
Eur J Neurol. 2023 May;30(5):1435-1442.